Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (BCP-ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1%.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/08/2019|
|Rapid review completed||23/09/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price.*|
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.